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Neurophysiological biomarkers may be useful for identifying the presence of schizophrenia and 
the schizophrenia prodrome among at-risk individuals prior to the emergence of psychosis.  This 
study examined the emitted P3 to absent stimuli on a tone counting task in patients with chronic 
schizophrenia and newly-diagnosed patients. The P3 is biphasic, with the earlier peak (P3a) 
reflecting automatic orienting and the later peak (P3b) reflecting cognitive processing. Twenty-
four individuals with long-term schizophrenia (minimum 5 years diagnosis; SZ) were compared 
to 24 matched controls (HCSZ), and 23 individuals within 6 months of their first psychotic 
episode (FE) were compared to 22 matched controls (HCFE). Participants were presented with 
standard sets of four identical tones (1 kHz, 50 ms, 330 ms SOA, 750 ms ITI). For one in seven 
sets, the fourth tone was missing. Participants simply counted the number of tones within each 
set, with no instruction to detect missing tones. The P3a emitted by missing tones was 
significantly reduced in SZ compared to HCSZ (p=.044).  The P3b emitted by missing tones was 
significantly reduced in both SZ and FE compared to their matched control groups (p=.049 and 
p=.036 respectively).  SZ and FE showed impaired generation of the emitted P3b during 
selective attention to stimuli. The emitted P3b may be useful to understand cognitive 
neuropathophysiology early in psychosis, and shows promise as a biomarker to help detect the 
true schizophrenia prodrome among clinical high risk individuals prior to disease onset. 
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1.0  INTRODUCTION 
Schizophrenia is a chronic psychiatric disorder that impacts a person’s thoughts and behaviors 
through various types of cognitive and physical symptoms.  Each individual experiences a 
varying degree of symptom severity, which can significantly impact their productivity in life and 
society.  The disease is associated with positive, negative, and cognitive symptoms (Liddle, 
1987).  Disease onset is defined by an individual’s first episode of psychosis, and the typical 
onset of schizophrenia occurs between ages of 16 and 40 (median = 27 for men, 35 for women 
(Loranger, 1984). Before first psychotic episode, cognition rapidly declines, which is related to 
grey matter shrinkage and ventricle enlargements.  This cognitive decline stays relatively stable 
after diagnosis (Lewandowski, Cohen, & Öngur, 2011).  Cognition rarely returns to pre-
psychosis levels of functioning (Insel, 2010).  Therefore, there is a need to identify and treat 
individuals who are at risk of developing schizophrenia before their first psychotic episode in 
order to avoid the disease-associated cognitive decline. 
 Identification of biomarkers for specific diseases like schizophrenia may aid in 
identifying the presence of disease early before the first psychotic episode.  Through identifying 
biomarkers, researchers in the future may work to reduce symptoms of schizophrenia or prevent 
disease onset to help an individual better function in society.  Past researchers have defined 
biomarkers as “cellular, biochemical or molecular alterations that are measurable in biological 
media such as human tissues, cells, or fluids” (Mayeux, 2004).  This definition includes any 
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biological events or characteristics than can be objectively evaluated as a measure of normal 
biological processes.  Biomarkers may be used to measure disease progression, symptom 
severity, or mark the presence of disease.  In the current study, we will investigate a potential 
biomarker that indicates the presence of schizophrenia. 
 The biomarker must be present in all individuals with the disease, including both patient 
groups who have the disease for a long time and those who have a recent onset of disease.   In 
the search for a biomarker for schizophrenia, the auditory system has become a key target due to 
the common presence of auditory hallucinations and deficits in auditory perception.  For 
example, approximately 70% of individuals with schizophrenia show auditory verbal 
hallucinations (Chaudhury, 2010), even at first break (Salisbury unpublished data), and 
Addington et al (2015) reported that 74.2% of their clinical high risk for schizophrenia 
participants experience perceptual aberrations or brief hallucinations.  Also, individuals with 
schizophrenia show deficits in pitch perception (Javitt, 2009), which are associated with reduced 
auditory event-related potentials (ERP) (O’Donnell, Vohs, Hetrick, Carroll, & Shekhar, 2004; 
Rosburg, Boutros, & Ford, 2008).  
 Auditory mismatch negativity (MMN) has been the historical favorite ERP to investigate 
as a potential biomarker for schizophrenia.  The MMN is a negative deflection in the 
electroencephalography (EEG) data in response to a novel stimulus (Näätänen, 1990).  EEG is a 
non-invasive electrophysiological monitoring method that records electrical activity of the brain.  
A standard auditory paradigm to elicit an MMN response is termed the ‘oddball paradigm.’  In 
this paradigm, identical tones are repeatedly played, and rare deviants that differ in tone pitch or 
duration are played infrequently.  The MMN is a cognitive event responding to the deviant tone, 
or deviation in a pattern (Todd, Michie, Schall, Ward, & Catts, 2012), thought to serve as the 
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perceptual trigger for the orienting response.  Patients with schizophrenia reliably show reduced 
MMN (Umbricht & Krljes, 2005), indicating poor deviance detection in the disorder.  Using 
MMN has a biomarker has failed, however, to produce consistent results among people newly 
diagnosed with schizophrenia.  Previous studies have consistently shown large effect sizes for 
MMN reduction in chronic schizophrenia groups (Umbricht & Krljes, 2005), but medium to 
small effect sizes in MMN reductions in first-episode patient groups (Erickson, Ruffle, & Gold, 
2016; Haigh, Coffman, Murphy, Butera, & Salisbury, 2016). This is important because we know 
that individuals in their first-episode of schizophrenia have the disease, but are earlier in the 
disease course.  Therefore, a biomarker of disease presence should be abnormal at first-episode, 
as well as in chronic stages. Instead, this suggests that MMN responses may be affected by 
duration of disease, which is interesting for measuring changes in pathophysiology of 
schizophrenia or a biomarker of disease progression.  This makes the MMN ERP insufficient for 
a biomarker of disease presence prior to the onset of actual psychotic symptoms.   
 This study hypothesizes that the emitted P3 would serve as a biomarker of disease 
presence.  P3 as a general ERP is pathophysiologically relevant to schizophrenia, as it describes 
a variety of cognitive functions, such as attention, orienting, effort, and memory performance.  
Past research has replicated decreased amplitude of P3 in response to auditory stimuli in people 
with schizophrenia, aiding in its use as an efficient biomarker (Pfefferbaum, Ford, White, & 
Roth, 1989).  These reductions in P3 amplitude support the view that disease course in 
schizophrenia leads to a core deficit of dysfunction in working memory and attention (Van der 
Stelt, Frye, Lieberman, & Belger, 2004).  Deficits in working memory and attention may be 
characterized by noticing dysfunction in auditory pattern analysis.  To serve as a biomarker of 
disease presence, it is expected to see a P3 abnormality in patients with chronic schizophrenia, as 
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well as patients newly diagnosed with schizophrenia. For example, in the standard oddball P3 
task, where participants count the oddballs, both chronically ill and first episode psychosis 
participants show P3 reductions (Salisbury, Shenton, & McCarley, 1999). 
 The P3 ERP is typically the third positive electrical event elicited after stimulus onset, 
occurring 300 ms after onset (Sutton, Braren, Zubin, & John, 1965).  The P3 component can 
occur in response to an infrequent task-relevant event (Begleiter et al., 1998).  P3 can be used to 
assess cognitive functions in healthy and diseased patients because of P3’s properties of a 
cognitive marker and its reliability in measuring specific time-related events.  Since P3 is 
generated in response to subjects’ attending to and discrimination of different stimuli, it is 
expected that the P3 complex relates to attention allocation, information processing mechanisms, 
and immediate memory (Polich & Kok, 1995).  The measurement of time-locked events provides 
insight into the functioning of the brain, especially in terms of working memory and stimuli 
processing.  People with schizophrenia consistently show deficits in attention (Green, 1996) and 
novelty detection (Javitt, Shelley, & Ritter, 2000).  These qualities make P3 complex a good 
candidate to investigate for a potential biomarker in measuring disease presence.  
 P3 is often constituted of two separate events: P3a and P3b (Squires, Wickens, Squires, & 
Donchin, 1976).  A distinct presence of both P3a and P3b create a bimodal distribution of 
neuroelectrical activity and generate the entire P3 complex.  Past literature finds that the P3a 
event reflects more automatic processing and orienting to salient stimuli whereas P3b reflects 
more deep and controlled cognitive processing of task-relevant events (Polich, 2007; Polich & 
Criado, 2006).   
 A complex auditory pattern paradigm was chosen to study the presence of P3 complex in 
schizophrenia.   Previous research hypothesizes that complex patterns tend to be more sensitive 
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to cognitive abnormalities in evaluating auditory patterns (Salisbury & McCathern, 2016).  This 
hypothesis is relevant when testing first-episode patients, because their working memory deficits 
may not be robustly seen in simple pattern tasks.  Additionally, more cognitively demanding 
tasks tend to elicit larger P3 responses, and larger deficits in diseased individuals (Javitt, 
Spencer, Thaker, Winterer, & Hajós, 2008).  For these reasons, this study examined the use of a 
complex auditory task to elicit the P3 complex.   
 In addition to the oddball tasks referenced above, P3 can also be elicited by the absence 
of an expected stimulus. This is termed the “emitted” P3 (Ruchkin & Sutton, 1978).  Results 
from studies using P3 responses from oddball tasks cannot be assumed to be equivalent in 
emitted tasks.  Since each task requires different mechanisms of processing, the elicited 
responses will reflect different neural and cognitive activities.  Deficits in P3 elicited in response 
to oddball or infrequent stimuli paradigms in chronic schizophrenia have long been reported 
(Ford, Pfefferbaum, & Roth, 1992; Levit, Sutton, & Zubin, 1973; Roth & Cannon, 1972), 
however, little studies on emitted P3 impairments in chronic or first-episode schizophrenia exist. 
 This study compared the emitted P3 complex between individuals with chronic 
schizophrenia, individuals at their first-episode of schizophrenia, and their matched healthy 
controls. Participants heard groups of 4 tones with infrequent deviant groups only containing 3 
tones. Participants counted the number of tones in a group, and it was expected that subjects 
would develop an expectancy for four tones per group. Hence, the absence of the fourth tone 
would evoke an emitted P3 response. By examining chronic and first-episode patients, the 
emitted P3 complex can validated as abnormal in long-term illness, investigated for 
abnormalities at first break, and evaluated as a potential biomarker for the disease presence of 
schizophrenia prior to actual psychosis. 
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2.0  METHODS AND MATERIALS 
2.1 PARTICIPANTS 
Twenty-four participants with chronic schizophrenia (SZ) were compared with 24 matched 
healthy control (HCSZ) participants.  SZ had at least 5 years length of illness or were 
hospitalized at least three times for psychosis.  Sixteen SZ had a diagnosis of schizophrenia 
(undifferentiated = 4; paranoid = 6; residual = 5; disorganized = 1), and 8 had schizoaffective 
disorder (depressed type = 1, bipolar type = 1, not specified = 6). Twenty-three participants 
newly diagnosed with psychosis in the schizophrenia spectrum (FE) were compared with 22 
matched healthy control (HCFE) participants.  FE had a first episode of psychosis within six 
months of participation in the study. Nine FE had a diagnosis of paranoid schizophrenia, 2 had a 
diagnosis of undifferentiated schizophrenia, 3 had a diagnosis of schizophreniform disorder, 7 
had a diagnosis of a psychotic disorder not otherwise specified, and 2 had a diagnosis of 
schizoaffective disorder depressed type.  All subjects had normal hearing as assessed by 
audiometry, at least nine years of schooling, and an estimated IQ over 85 (Wechsler Abbreviated 
Scale of Intelligence, WASI).  None of the participants had a history of concussion or TBI with 
sequelae, history of alcohol or drug addiction, or detox in the last five years, or neurological 
comorbidity.  Control subjects additionally had no psychiatric illnesses.  Groups were matched 
for age, estimated premorbid IQ, and parental socioeconomic status.  The 4-factor Hollingshead 
6
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Scale was used to measure socioeconomic status (SES) in participants and in their parents. As 
expected, SZ had lower SES than HCSZ, and FE hand lower SES than HCFE, consistent with 
social and occupational impairment as a disease consequence (see Table 1 for demographic 
measures). All participants provided informed consent after receiving a complete description of 
the study, and were paid for participation.  The study was approved by the University of 
Pittsburgh IRB. 
 Table 1. Subject Demographics. Demographic data of all four experimental groups.  Statistic values for comparisons are shown, either chi-squared test 
or t-test where appropriate.  Significant differences in matched groups are bolded. 
 HCFE FE Statistics HCSZ SZ Statistics 
Number of Subjects 22 23  24 24  
Age 25.6 (9.6) 22.3 (5.5) t(43)=1.4, p=.16 32.7 (9.3) 35.6 (7.6) t(46)=-1.2, p=.23 
Gender 7 F/15 M 8 F/15 M x²=0.44, p=.83 8 F/16 M 8 F/15 M x²=.01, p=.92 
% Right Handed 75% 89.4% x²=4.44, p=.22 95.8% 88% x²=4.09, p=.25 
Subject SES 37.8 (13.1) 27.0 (12.1) t(38)=2.69, p=.01 38.3 (12.2) 30.5 (12.1) t(44)=2.17, p=.04 
Parental SES 49.6 (11.4) 44.7 (12.1) t(41)=1.35, p=.18 41.8 (9.8) 37.8 (13.3) t(45)=1.16, p=.25 
IQ 106.9 (9.1) 108.3 (14.1) t(43)=-.39, p=.69 103.01 (9.6) 105.8 (11.5) t(46)=-.89, p=.38 
MATRICS 29.18 (2.3) 28.4 (4.1) t(43)=.79, p=.44 27.9 (2.4) 27.0 (4.3) t(46)=.92, p=.36 
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2.2 DIAGNOSTIC ASSESMENTS 
Diagnosis was based on the Structured Clinical Interview for DSM-IV (SCID-P). Symptoms 
were rated using the Positive and Negative Symptom Scale (PANSS), Scale for Assessment of 
Positive Symptoms (SAPS), and Scale for Assessment of Negative Symptoms (SANS). All tests 
were conducted by an expert diagnostician. SZ were medicated and moderately symptomatic.  
Only 67% of FE subjects were medicated (see Table 1 for clinical measures).   
2.3 NEUROPSYCHOLOGICAL TESTS 
All participants completed the MATRICS Consensus Cognitive Battery and the WASI. Social 
functioning was assessed with the brief UCSD Performance-based Skills Assessment (UPSA-B. 
See Table 1 for neuropsychological test scores). 
2.4 PROCEDURE 
Stimuli were generated with Tone Generator (NCH Software) and presented in Presentation 
(Neurobehavioral Systems, Inc.). Binaural auditory stimuli were delivered using Etymotic 3 A 
insert earphones, with loudness confirmed with a sound meter. 
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2.5 STIMULI FOR AUDITORY PARADIGM 
All tones had identical physical parameters of 1 kHz, 50 ms pips with 5 ms rise/fall times, 80 dB. 
Temporal proximity was used to form discrete groups, with a SOA within groups of 330 ms. 
Groups were separated by an ITI of 750 ms. Four tones formed the standard group. The deviant 
group consisted of three tones, omitting the fourth tone. Deviant groups were presented 14.3% of 
the time, with a total of 50 deviant groups.  Deviant groups never followed one another. 
Participants were instructed to internally count the number of tones that played within each 
group.  Triggers were embedded in the EEG file for each tone and for missing but expected 4th 
tones. 
2.6 ELECTROENCEPHALOGRAM (EEG) RECORDING AND PROCESSING 
EEG was recorded from a custom 72 channel Active2 high impedance system (BioSemi), 
comprising 70 scalp sites including the mastoids, 1 nose electrode, and 1 electrode below the 
right eye. The EEG amplifier bandpass was DC to 104 Hz (24 dB/octave roll off) digitized at 512 
Hz, referenced to a common mode sense site (near PO1).  Processing was done off-line with 
EEGLAB (Delorme & Makeig, 2004) and BrainVision Analyzer2 (Brain Products GMBH). 
First, using EEGLAB, EEG was filtered at 0.5 Hz to remove DC drifts and skin potentials. Data 
were visually examined and any channels with excessive noise were interpolated. Adaptive 
Mixture ICA (Palmer et al., 2007; Delorme et al., 2012) was used to remove one vertical and one 
horizontal EOG component.  Next, in BrainVision Analyzer2, data were filtered at 20 Hz to 
remove muscle and other high frequency artifact, and were rereferenced to the mastoids. Epochs 
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of 650 ms were extracted to include all ERP responses from the deviant missing fourth tone until 
just prior to the first tone of the next group.  Epochs were extracted from the EEG based on 
stimulus triggers, including a 50 ms prestimulus baseline. Epochs were baseline corrected. 
Epochs were subsequently rejected if any site contained activity ±50 μV. Averages were 
constructed for the “missing” 4th tone. 
2.7 DATA ANALYSIS OF EMITTED P3 
Emitted P3a to the omitted stimulus was measured from electrode site Fz and P3b from electrode 
site Pz.  The 50 msec window measurement intervals were centered on the P3 peak in healthy 
control groups.  For SZ and HCSZ, P3a was measured between 350 ms and 400 ms after the 
omitted fourth tone.  P3b was measured between 360 ms and 410 ms after the stimulus should 
have occurred.  For FE and HCFE, P3a was measured between 250 ms and 300 ms after the 
fourth tone should have been played.  P3b was measured between 350 ms and 400 ms after the 
stimulus should have occurred.  P3a and P3b ERPs were subjected to current source density 
(CSD) analysis to infer source-sink topography.  Interpolation was done using spherical splines, 
with the order of splines set to 4, the maximum degree of Legendre polynomials set to 10, and a 
default lambda of 1e-5.   
 11 
2.8 STATISTICS 
Group demographics were compared using t-tests and chi-squared tests where appropriate. 
Emitted P3a analysis was performed at Fz and emitted P3b analysis was performed at Pz, using 
independent samples t-tests.     
Two-tailed Spearman's correlations were used to examine relationships between P3a and 
P3b components at Fz and Pz (respectively) and demographic, clinical, and neuropsychological 
items. Values are reported as Mean ±SD. Significance was attained at p <.05. 
12
3.0  RESULTS 
3.1 EMITTED P3 IN PATIENTS WITH CHRONIC SCHIZOPHRENIA 
SZ and HCSZ showed a significant difference between their P3a ERP responses. SZ had a 
significantly smaller P3a response (0.92 ±1.87 µV) than HCSZ (2.18 ±2.31 µV; t(46)=2.07, 
p=.044).  Figure 1a shows the P3a ERP waveforms for SZ and HCSZ, as well as the scalp 
topography and CSD distribution maps.  The voltage topography maps for both SZ and HCSZ 
show expected frontal-central distribution for a P3a ERP.  The CSD for both groups show a 
likely source of the P3a ERP located in anterior regions. 
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 Figure 1a. Emitted P3a for SZ and HCSZ. (From Left to Right) Scalp topography and current source 
density (CSD) maps of the P3a response to the deviant group in HCSZ; Waveforms of P3a ERP response at Fz 
(HCSZ in black, SZ in red); Scalp topography and CSD maps of the P3a response to the deviant group in SZ.  
 
Figure 1b. Emitted P3b for SZ and HCSZ. (From Left to Right) Scalp topography and CSD maps of the 
P3b response to the deviant group in HCSZ; Waveforms of P3b ERP response at Pz (HCSZ in black, SZ in red); 
Scalp topography and CSD maps of the P3b response to the deviant group in SZ. 
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SZ also produced a significantly smaller P3b response (0.50 ±1.87 µV) than HCSZ 
(1.90±2.81 µV; t(46)=2.02; p=0.049).  Figure 1b shows the P3b ERP waveforms for SZ and 
HCSZ, as well as the scalp topography and CSD distribution maps.  The voltage topography map 
for HCSZ shows the expected distribution of P3b, with positivity in a more centro-posterior 
region.  The topography map for SZ, however, shows an abnormally frontal positivity for what is 
expected for P3b response.  The CSD map in HCSZ generally shows an expected source for the 
P3b response, occurring in a posterior temporo-parietal region.  The CSD map in SZ shows an 
abnormal source for P3b occurring in a more anterior region than what is expected, mostly likely 
reflecting continued P3a activity with little P3b activity in that group. 
3.2 EMITTED P3 IN PATIENTS WITH FIRST-EPISODE SCHIZOPHRENIA 
FE (1.15 ±2.30 µV) and HCFE (1.58 ±1.80 µV) showed no difference in P3a ERP responses 
(t(43)= 0.69, p>.49).  Figure 2a shows the P3a ERP waveforms for FE and HCFE, as well as the 
scalp topography and CSD distribution maps.  The voltage distribution maps for both FE and 
HCFE show expected distributions for a P3a ERP, with positivity over the frontal-central scalp. 
The CSD for both groups show a likely source of the P3a ERP located in anterior regions.  
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 Figure 2a. Emitted P3a for FE and HCFE. (From Left to Right) Scalp topography and CSD maps of the 
P3a response to the deviant group in HCFE; Waveforms of P3a ERP response at Fz (HCFE in black, FE in blue); 
Scalp topography and CSD maps of the P3a response to the deviant group in FE.  
 
Figure 2b. Emitted P3b for FE and HCFE. (From Left to Right) Scalp topography and CSD maps of the 
P3b response to the deviant group in HCFE; Waveforms of P3b ERP response at Fz (HCFE in black, FE in blue); 
Scalp topography and CSD maps of the P3b response to the deviant group in FE. 
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FE produced a significantly smaller P3b response (-0.15 ±1.99 µ) than HCFE (1.28 ±2.46 
µV; t(43)=2.17; p=0.036).  Figure 2b shows the P3b ERP waveforms for FE and HCFE, as well 
as the scalp topography and CSD distribution maps.  The voltage topography map for HCFE 
shows the expected distribution of P3b, with positivity in a more centro-posterior area.  The 
topography map for FE, however, shows an abnormal positivity for what is expected for P3b, 
reflecting an asymmetrical positivity occurring in the occipital region.  The CSD map in HCFE 
generally shows an expected source for the P3b response, occurring in temporo-parietal regions. 
The CSD map in FE shows an abnormal source for P3b occurring in a more frontal region than 
what is expected. 
3.3 CORRELATIONS WITH CLINICAL AND COGNITIVE VARIABLES 
3.3.1 HCSZ 
The HCSZ group had no demographic or neuropsychological factors that correlated with P3a or 
P3b ERPs.   
3.3.2 SZ 
Parental SES positively correlated with P3b ERP response (r(23)=.544, p=.007), such that higher 
pSES was reflected in larger P3b. 
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Figure 3. SZ pSES and P3b Correlation. Correlation scatterplot graph of SZ experimental group 
comparing P3b ERP responses to parental SES scores 
3.3.3 HCFE 
A positive correlation existed between HCFE’s P3a and years of education (r(21)=.497, p=.028), 
such that more years of education was reflected in larger P3a.    
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Figure 4. HCFE Education and P3a Correlation. Correlation scatterplot graph of HCFE experimental 
group comparing P3a ERP responses to years of education 
3.3.4 FE 
The FE group had no demographic factors or psychiatric symptom scores that correlated with 
P3a or P3b ERPs.   
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4.0  DISCUSSION 
The novel contribution of this experiment is that we examined P3 in response to an omitted 
stimulus, which has not been previously examined in FE.  FE showed a healthy emitted P3a 
when compared to their matched healthy controls, while SZ had a significantly impaired emitted 
P3a compared to their matched healthy controls.  Both patient groups also had significantly 
impaired emitted P3b responses compared to their controls.  When referencing the CSD and 
topography maps, HCSZ appears to have a mix of P3a and P3b distributions.  This distribution is 
not seen in SZ. Since P3b is significantly reduced, any activity reflected in these distributions is 
likely noise or residual P3a and not true brain activity reflecting P3b.  The distribution of P3a 
and P3b were as expected in healthy comparison individuals.  This study supports earlier reports 
of decreased P3b in chronic schizophrenia patient populations (Kiehl & Liddle, 2001), but 
expands on the research concerning first-episode patients by concluding that P3b responses are 
also reduced in first-episode patient groups (Salisbury et al., 1999).  
A general decrease of the emitted P3 is thought to reflect inappropriate attention resource 
allocations during tasks (Demiralp et al., 2002).  P3a deficits, specifically, reflect problems in the 
automatic orienting to salient stimuli.  Healthy P3a responses in the first-episode patient group 
validates the saliency of the stimulus task, meaning that FE have the ability to attend to the 
stimuli.  SZ impairments in P3a indicate that development of chronic disease in schizophrenia 
creates deficits in orienting to salient or deviant stimuli.  A reduction in P3b is more directly 
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related to deep, controlled processing of task-relevant information deficits.  The distribution of 
P3b in this study is consistent with an expected distribution around the temporo-parietal region, 
and this brain region is implicated in attention, working memory, and other memory-related 
processes.  Impaired neural activity in these brain regions in patients with schizophrenia may be 
related to dysfunction in cognitive tasks related to memory processing (Kiehl & Liddle, 2001). 
FE deficits in P3b may be related to poor resource allocation for cognitive tasks.  A healthy P3a 
but impaired P3b in FE suggests that first-episode schizophrenia is associated with the automatic 
detection of the missing stimulus, yet the information does not appear to receive further higher 
order cognitive processing.  SZ exhibit both P3a and P3b impairments, indicating deficits in 
attention orienting and impairments in controlled deep processing of stimuli.  In the case of an 
expected but missing stimulus, this suggests that in chronic schizophrenia, deficits in both the 
automatic detection and higher order cognitive processing exist. 
The results of this study support the conclusion that aspects of attention or working 
memory may be impaired in people with schizophrenia rather than a component of the sensory 
system being impaired.  Since P3a, the more automatic orienting to sensory stimuli component of 
the emitted P3, is not significantly reduced in FE group, sensory orienting of the FE patient 
group does not seem to be impaired.  Both P3a and P3b are impaired in SZ, however.  This 
indicates that deficits in P3b are not related to abnormalities in hearing the tones or structural 
abnormalities in the auditory cortex, but abnormalities in the top-down processing and control of 
sensory information.  While top-down processing and resource allocation is impaired before the 
disease is diagnosed, sensory responses may degrade with the progress of disease. 
Correlational analysis between emitted P3 and cognitive and neurological assessment 
scores showed no association between symptoms and emitted P3 impairments.  When doing 
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correlational analysis, we looked at PANSS total, negative, and positive scores.  If one factor 
appeared significant, we analyzed the subcategories to see what dimension was driving the 
correlation with the larger factor.  Analysis in this method showed no association between 
symptom severity and ERP responses.  Several demographic factors were correlated with emitted 
P3 responses.  A positive correlation between SZ emitted P3b and parental SES indicate that 
healthier ERP responses are associated with a more affluent background.  A positive correlation 
between HCFE emitted P3a and years of education indicate that healthier ERP responses are 
associated with higher education.  Both correlations insinuate that healthier ERP responses 
indicate a higher quality of life, which may be expected in patient groups.  These correlations are 
highly exploratory, and further research in this direction should be pursued to extract meaningful 
conclusions from this data.
P3b deficits may relate to impairments in general functioning that is seen in patients 
with schizophrenia.  A disturbance of top-down control and cognitive processing of stimuli is 
linked to clinical disturbances in motivation, attention, and reality testing (Turetsky, Bilker, 
Siegel, Kohler, & Gur, 2009).  Deficits in P3b during emotional categorization tasks 
hypothesize that P3 may be involved in encoding and deep processing of salient information, 
like emotion (Johnston, Stojanov, Devir, & Schall, 2005).  These clinical disturbances 
could relate to some of the hallmark symptoms seen in patients with schizophrenia. 
In terms of practical clinical application, the results of this study show that emitted P3b 
is a promising physiological event to use as a biomarker of disease presence.  Emitted P3a was 
not significantly reduced in the first episode patient group compared to the first-episode 
patients or healthy controls, so it is an insufficient event to use as a biomarker to determine 
which among the clinical high risk individuals might covert to psychosis.  Emitted P3b, 
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however, was significantly reduced in both chronic and first episode groups, showing it is 
affected early in the disease course in those known to have schizophrenia.  Past research as 
sought to use oddball P3b, rather than emitted P3b, as a biomarker for schizophrenia.  Although 
oddball P3b is reduced in true prodromal cases (van Tricht et al., 2010), it is also 
somewhat reduced in a large percentage of ultra-high risked non-converters (Bramon et al., 
2008; Özgürdal et al., 2008; Van der Stelt et al., 2004). This may indicate general cognitive 
impairment common to the at risk individuals rather than the specific presence of the 
psychosis prodrome. Emitted P3b, however, may be a specific biomarker for schizophrenia 
prodomal phase, rather than identifying high risk individuals.  If emitted P3b is unique to 
psychosis prodrome, specific diagnostic techniques and therapies may be used effectively and 
efficiently to target patients before they enter first episode psychosis.  
One limitation of this study is that some of the chronic and first-episode patients were 
on medications.  However, no significant effect of antipsychotic medications on P3 have 
been reported (An et al., 2003; Condray, Steinhauer, Cohen, van Kammen, & Kasparek, 1999; 
Ford et al., 1994; Pfefferbaum et al., 1989).  We are, however, ethically obligated to treat 
patients, so this is an intractable issue for most work in schizophrenia. 
 Future directions include conducting this experiment in individuals in the prodromal 
phase of schizophrenia.  If this task is to be used to identify biomarkers that show disease 
presence, an impaired emitted P3b should be elicited in prodromal individuals.  Several 
other biomarkers of disease presence have been identified.  If the emitted P3b adds unique 
predictive power to the slate of measures, it may prove a valuable addition to the screening 
battery.  Overall, the emitted P3 response to omitted stimuli showed abnormalities in long-
term and in first episode schizophrenia, specifically in the emitted P3b in both groups and the   
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emitted P3a in long-term illness.  Hence, the emitted P3b shows promise as serving as a 
biomarker due to its significant reduction even at first-episode, and may be useful for 
detecting disease presence in schizophrenia, prior to the emergence of overt psychosis.   
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